Probing In Silico the Benzimidazole Privileged Scaffold for the Development of Drug-like Anti-RSV Agents

• Váldodahkkit: Elena Cichero (Dahkki), Alessio Calautti (Dahkki), Valeria Francesconi (Dahkki), Michele Tonelli (Dahkki), Silvia Schenone (Dahkki), Paola Fossa (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2021-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Targeting the fusion (F) protein has been recognized as a fruitful strategy for the development of anti-RSV agents. Despite the considerable efforts so far put into the development of RSV F protein inhibitors, the discovery of adequate therapeutics for the treatment of RSV infections is still awaiti...